TOPICS / TUMOR TYPE

Head & neck cancer

Head-and-neck squamous-cell carcinoma (HNSCC) — a frequent neoantigen-vaccine setting.

Topic2 items2026-05-31 – 2026-06-02

Tumor types

Melanoma10 Pancreatic cancer9 Glioblastoma9 Colorectal cancer7 Lung cancer (NSCLC)6 Lynch syndrome5 Kidney cancer (RCC)5 Breast cancer5 Head & neck cancer2 Liver cancer (HCC)2 Gastric cancer1 Bladder cancer1 Prostate cancer1

Clinical

Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

UNC Lineberger Comprehensive Cancer Center has suspended a Phase I trial of the PANDA-VAC personalized neoantigen peptide vaccine administered concurrently with pembrolizumab. The study was designed for advanced squamous NSCLC and head and neck squamous cell carcinoma, assessing safety and dose adjustment protocols.

clinicaltrials · brief 2026-06-02 · published 2026-04-23

Clinical

Phase I Trial of Neoantigen Vaccine Shows 100% DFS Rate in HNSCC - Targeted Oncology

A Phase I trial of a neoantigen vaccine reported a 100% disease-free survival rate in head and neck squamous cell carcinoma (HNSCC). This outcome underscores the potential for personalized vaccines to achieve durable remission in specific solid tumor indications.

news · brief 2026-05-31 · published 2026-01-12